Enveric Biosciences Completes Manufacturing Of EB-373 To Supply Drug Material For Completion Of Preclinical Program
Portfolio Pulse from Happy Mohamed
Enveric Biosciences (NASDAQ:ENVB) has completed the manufacturing of its drug material, EB-373, enabling the completion of preclinical work. The company will now commence remaining GLP studies to provide data required to initiate human trials for EB-373. The company expects to complete all remaining preclinical studies required for Human Research Ethics Committee (HREC) submission in Australia before the end of 2023. The high purity of EB-373 allows Enveric and its partners to handle and ship the drug without restrictions required for controlled substances.
August 21, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enveric Biosciences has completed the manufacturing of EB-373, a key step towards initiating human trials. The high purity of the drug allows for unrestricted handling and shipping, potentially saving time and costs.
The completion of the manufacturing of EB-373 is a significant milestone for Enveric Biosciences, as it enables the company to proceed with the remaining GLP studies required to initiate human trials. The high purity of the drug, which allows for unrestricted handling and shipping, could potentially save the company time and costs in the future. This news is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100